Salivary gland cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Salivary gland cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Zanidatamab for Patients with Previously Treated HER2-Expressing Solid Tumors https://clinicaltrials.eu/trial/a-study-of-zanidatamab-for-patients-with-previously-treated-her2-expressing-solid-tumors/ Thu, 30 Apr 2026 13:08:23 +0000 https://clinicaltrials.eu/trial/a-study-of-zanidatamab-for-patients-with-previously-treated-her2-expressing-solid-tumors/ This study is looking at patients who have solid tumors that show a protein called HER2 on their surface. These are cancers that have spread or grown in a way that cannot be removed by surgery, and previous treatments have not worked. The study will use a medicine called zanidatamab, which is also known by its code name JZP598. This medicine is given through a needle into a vein over a period of time, known as an infusion. The purpose of the study is to see how well zanidatamab works against these tumors and how safe it is for patients to use.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

]]> Safety of injecting bupivacaine and dexamethasone into the parotid gland for patients undergoing surgery for a benign parotid tumor https://clinicaltrials.eu/trial/safety-of-injecting-bupivacaine-and-dexamethasone-into-the-parotid-gland-for-patients-undergoing-surgery-for-a-benign-parotid-tumor/ Wed, 29 Apr 2026 15:09:34 +0000 https://clinicaltrials.eu/trial/safety-of-injecting-bupivacaine-and-dexamethasone-into-the-parotid-gland-for-patients-undergoing-surgery-for-a-benign-parotid-tumor/ This study focuses on patients undergoing a parotidectomy, which is a surgical procedure to remove part of the parotid gland, a large salivary gland located in front of the ear. The surgery is performed to treat a benign tumor, which is a non-cancerous growth in the gland. The purpose of the study is to evaluate the safety and side effects of a specific medication mixture injected directly into the area of the gland during the operation.

The treatment involves an injection of two substances: bupivacaine, a local anesthetic used to numb the area and reduce pain, and dexamethasone, a steroid used to decrease swelling and inflammation. Following the surgery, participants will be monitored for up to 15 days to track pain levels, the healing process, and any potential complications such as a salivary fistula, which is an abnormal opening that allows saliva to leak out of the gland.

]]> Study of Capecitabine for Patients with Recurrent or Metastatic Salivary Duct Carcinoma https://clinicaltrials.eu/trial/study-of-capecitabine-for-patients-with-recurrent-or-metastatic-salivary-duct-carcinoma/ Wed, 29 Apr 2026 15:03:30 +0000 https://clinicaltrials.eu/trial/study-of-capecitabine-for-patients-with-recurrent-or-metastatic-salivary-duct-carcinoma/ This clinical trial is focused on studying a type of cancer known as Salivary Duct Carcinoma, which affects the salivary glands. The trial is investigating the effects of a medication called Capecitabine. This medication is taken orally and is being tested to see how well it works for patients with this specific type of cancer that has either returned or spread to other parts of the body.

The purpose of the study is to evaluate the overall response rate to Capecitabine in treating recurrent or metastatic salivary duct carcinoma. Participants in the study will receive the medication over a period of time, and researchers will monitor their response to the treatment. The study aims to gather information on how the cancer responds to the medication, how long patients can live without the disease getting worse, and the overall survival rate. Additionally, the study will assess the safety of the medication and its impact on the quality of life of the participants.

Throughout the study, researchers will collect data to understand the clinical benefits and control of the disease provided by Capecitabine. The trial is expected to continue until the end of 2029, with recruitment of participants starting in early 2025. This research is important for finding new ways to manage and treat salivary duct carcinoma, especially for those whose cancer has not responded to other treatments.

]]> Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ Wed, 29 Apr 2026 15:03:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-bay-2927088-for-patients-with-advanced-solid-tumors-with-her2-mutations/ This clinical trial is focused on studying the effects of a new treatment for people with advanced solid tumors that have a specific change in their genes known as a HER2 mutation. The treatment being tested is a medication called BAY 2927088, which is taken as a coated tablet. This medication is a type of drug known as a reversible tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

]]> Study on Sentinel Lymph Node Biopsy for Parotid Gland Cancer Using Gallium (68Ga) Chloride and Tilmanocept in Patients Undergoing Parotidectomy and Neck Dissection https://clinicaltrials.eu/trial/study-on-sentinel-lymph-node-biopsy-for-parotid-gland-cancer-using-gallium-68ga-chloride-and-tilmanocept-in-patients-undergoing-parotidectomy-and-neck-dissection/ Wed, 29 Apr 2026 14:27:24 +0000 https://clinicaltrials.eu/trial/study-on-sentinel-lymph-node-biopsy-for-parotid-gland-cancer-using-gallium-68ga-chloride-and-tilmanocept-in-patients-undergoing-parotidectomy-and-neck-dissection/ This clinical trial is focused on studying a type of cancer called carcinoma of the parotid gland, which affects the salivary glands located near the ear. The study aims to explore a procedure known as sentinel lymph node biopsy (SLNB) in patients who are scheduled for surgery to remove the parotid gland and possibly some lymph nodes in the neck. The procedure involves using a combination of two substances: 99mTc-nanocolloid and 68Ga-tilmanocept, which are used in a special type of imaging called PET/CT to help identify the lymph nodes that may be affected by cancer.

The purpose of the study is to determine if this method can effectively identify the sentinel lymph nodes in patients with parotid gland carcinoma. During the study, patients will undergo the SLNB procedure, and the researchers will use the imaging technique to locate the lymph nodes. The goal is to see if the imaging can successfully identify these nodes in at least 8 out of 10 patients. The study will also compare the results of the lymph node biopsy with the results from the neck dissection surgery to check for the presence of cancer cells.

Additionally, the study will look into the best timing for the PET/CT imaging and assess any complications that may occur after the surgery. The findings from this study could help improve the way doctors identify and treat lymph nodes affected by cancer in patients with parotid gland carcinoma.

]]> Study on the Effectiveness of Dutasteride with Goserelin Acetate and Bicalutamide in Patients with Recurrent or Metastatic Salivary Duct Carcinoma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-dutasteride-with-goserelin-acetate-and-bicalutamide-in-patients-with-recurrent-or-metastatic-salivary-duct-carcinoma/ Wed, 29 Apr 2026 14:25:14 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-dutasteride-with-goserelin-acetate-and-bicalutamide-in-patients-with-recurrent-or-metastatic-salivary-duct-carcinoma/ This clinical trial is focused on studying a type of cancer called Salivary Duct Carcinoma, which affects the salivary glands. The study is investigating the effectiveness of a treatment that combines a medication called Dutasteride with a therapy known as combined androgen blockade. This therapy involves using medications that block male hormones, which can help slow the growth of certain types of cancer. The medications used in this study include Dutasteride, Zoladex, and Casodex. Zoladex is administered as an implant under the skin, while Casodex is taken orally as a tablet.

The purpose of the study is to determine how effective the combination of Dutasteride and combined androgen blockade therapy is in treating patients with recurrent or metastatic Salivary Duct Carcinoma. The study will compare the outcomes of patients receiving the combination treatment to those receiving only the combined androgen blockade therapy. Some participants will receive a placebo instead of Dutasteride to help researchers understand the treatment’s effects more clearly.

Participants in the study will receive treatment for a period of up to 12 months, with regular check-ups to monitor their health and the progress of the cancer. The study will also collect information on the overall response to the treatment, the duration of response, and any side effects experienced. The trial aims to provide valuable insights into the potential benefits of adding Dutasteride to the existing treatment regimen for this type of cancer.

]]>